Cantel Medical Corp. Launches RAPICIDE OPA/28 High-Level Disinfectant

Cantel Medical Corp. has officially launched RAPICIDE OPA/28, an ortho-phthalaldehyde (OPA) based high-level disinfectant for semi-critical medical devices, to multiple segments of the healthcare market. A 510(k) cleared product by the FDA, RAPICIDE OPA/28 high-level disinfectant offers a reuse period for up to 28 days, twice the reuse life among all OPA-based disinfectants available on the market, and the fastest manual disinfection time at 10 minutes at room temperature.

"We are very pleased to offer our latest disinfection product to broad segments of the healthcare market," says Andrew Krakauer, president and CEO of Cantel Medical Corp. "With close attention to healthcare cost control, increased scrutiny over healthcare-associated infections (HAIs), and higher demand for quality of care, we are excited that RAPICIDE OPA/28 high-level disinfectant is capable of lowering overall reprocessing costs among OPA-based disinfectants while delivering excellent product performance that will enhance the patients' and healthcare workers' use experience."

RAPICIDE OPA/28 is a convenient, ready-to-use high-level disinfectant designed for use in central processing departments, gastrointestinal departments, surgery centers, physician offices, and other areas where high-level disinfection is required. It can disinfect a wide range of endoscopes and other heat sensitive semi-critical medical devices. The product will be produced and sold via Cantel Medical Corp.'s subsidiaries: MEDIVATORS Inc., Crosstex International and SPSmedical.